Paysign マネジメント
マネジメント 基準チェック /34
Paysignの CEO はMark Newcomerで、 Mar2006年に任命され、 の在任期間は 20.17年です。 の年間総報酬は$ 2.75Mで、 38.1%給与と61.9%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の16.11%を直接所有しており、その価値は$ 62.32M 。経営陣と取締役会の平均在任期間はそれぞれ5.3年と8年です。
主要情報
Mark Newcomer
最高経営責任者
US$2.8m
報酬総額
| CEO給与比率 | 38.12% |
| CEO在任期間 | 20.2yrs |
| CEOの所有権 | 16.1% |
| 経営陣の平均在職期間 | 5.3yrs |
| 取締役会の平均在任期間 | 8yrs |
経営陣の近況
Recent updates
ナラティブの更新 • May 20
PAYS: Higher Margin Guidance And Premium P/E Framework Will Drive Repricing
Analysts have nudged their fair value estimate for Paysign up from $12.00 to $12.75, citing updated assumptions around growth, margins, and future P/E that fed into the latest price target increase highlighted in recent Street research. Analyst Commentary Recent Street research highlights a more constructive tone around Paysign, with bullish analysts pointing to the refreshed fair value estimate and updated assumptions as key supports for their views.ナラティブの更新 • Apr 30
PAYS: Higher Margin Outlook Will Support Repricing On Updated Profitability Assumptions
Analysts have raised their price target on Paysign by $1 to $12, citing updated assumptions around growth, profitability, discount rate and future P/E as the main drivers of this change. Analyst Commentary Bullish analysts are highlighting the recent price target move to US$12 as a sign of growing confidence in Paysign's outlook, with updated assumptions around growth, profitability, discount rate and future P/E at the core of their thesis.ナラティブの更新 • Apr 12
PAYS: Higher Margin Outlook And Raised P/E Assumption Will Support Repricing
Analysts lifted their Paysign price target by $1 to reflect slightly higher modeled revenue growth, modestly stronger profit margins, and an adjusted future P/E assumption, all under broadly consistent fair value and discount rate inputs. Analyst Commentary Bullish analysts framing the recent price target move highlight that the updated P/E assumption and slightly higher modeled revenue and margins support a higher fair value range for Paysign, while keeping discount rate inputs broadly consistent.ナラティブの更新 • Mar 28
PAYS: Higher Profit Margin Outlook Will Support More Constructive Share Repricing
The analyst price target for Paysign has increased from $9.50 to $12.00, with analysts citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E as key drivers of the change. Analyst Commentary Recent research points to a more constructive view on Paysign, with bullish analysts updating their models to reflect what they see as improved fair value assumptions and a more supportive outlook for key valuation inputs such as discount rate, revenue growth, profit margin and future P/E.分析記事 • Feb 05
The Price Is Right For Paysign, Inc. (NASDAQ:PAYS) Even After Diving 27%
Paysign, Inc. ( NASDAQ:PAYS ) shareholders that were waiting for something to happen have been dealt a blow with a 27...分析記事 • Nov 16
Paysign, Inc. Just Beat EPS By 100%: Here's What Analysts Think Will Happen Next
Paysign, Inc. ( NASDAQ:PAYS ) just released its quarterly report and things are looking bullish. The company beat...Seeking Alpha • Oct 01
Paysign: Gaining Traction In The Patient Affordability Space Into 2026 (Hold)
Summary Paysign posted strong Q2 2025 results, with 33% YoY revenue growth and robust Pharma segment momentum, driven by US tariffs and new client wins. PAYS is rated a hold, as the stock trades at fair value ($5.83), despite expected high demand for co-payment cards and expanded patient affordability programs. Pharma segment revenue surged 189% YoY, offsetting a 4.7% YoY decline in the core Plasma segment, which faces ongoing headwinds from transitioning centers. While PAYS benefits from industry tailwinds and guidance consistency, risks remain due to Plasma's weakness and Pharma revenues still lagging Plasma's overall contribution. Read the full article on Seeking Alpha分析記事 • Aug 09
Paysign, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
NasdaqCM:PAYS 1 Year Share Price vs Fair Value Explore Paysign's Fair Values from the Community and select yours One of...
ナラティブの更新 • Aug 07
Digital Payment Solutions Will Expand Healthcare Access Further
Analysts maintain a positive outlook on Paysign due to ongoing growth in its Patient Affordability segment, confidence in its pharmaceutical pipeline, and scalable model, resulting in no change to the consensus price target, which remains at $9.10. Analyst Commentary Bullish analysts highlight a strong outlook for Paysign's Patient Affordability segment, especially within the pharmaceutical industry.分析記事 • May 06
Paysign, Inc.'s (NASDAQ:PAYS) 28% Price Boost Is Out Of Tune With Earnings
Those holding Paysign, Inc. ( NASDAQ:PAYS ) shares would be relieved that the share price has rebounded 28% in the last...分析記事 • Mar 04
Paysign, Inc.'s (NASDAQ:PAYS) Share Price Not Quite Adding Up
With a median price-to-earnings (or "P/E") ratio of close to 18x in the United States, you could be forgiven for...分析記事 • Dec 27
Here's Why Paysign (NASDAQ:PAYS) Has Caught The Eye Of Investors
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Seeking Alpha • Nov 20
Paysign Is A Leader In Fintech Healthcare Payments With Durable Profitable Growth
Summary Paysign is a promising microcap payment processing company with a projected 42% annualized return, potentially reaching $19/share by 2030 from $3.30/share today. The company excels in two primary sectors: plasma payment processing and pharma patient affordability, both offering significant growth and high gross margins. PAYS's plasma business boasts a 40% market share with steady 10-15% annual growth, while the pharma segment is expected to surpass plasma with rapid expansion. Risks include increased competition, potential loss of key customers, and limited financial resources, but catalysts like market share gains and acquisition potential bolster the investment thesis. Read the full article on Seeking Alpha
新しいナラティブ • Sep 26
Rapid Growth In Patient Affordability Market Fuels Optimism Despite Looming Margin Pressures
The expansion into the patient affordability segment and significant client growth, like AstraZeneca, indicates a promising area for revenue and earnings increases.分析記事 • Sep 07
Do Paysign's (NASDAQ:PAYS) Earnings Warrant Your Attention?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...分析記事 • Aug 02
Paysign, Inc. (NASDAQ:PAYS) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Paysign, Inc. ( NASDAQ:PAYS ) shareholders are probably feeling a little disappointed, since its shares fell 7.1% to...Seeking Alpha • Jun 30
Paysign: Expect Rapid Growth In Its Pharma Business
Summary Shares have risen sharply this year, reflecting solid business performance. Its pharma segment is experiencing exceptional growth and has a long runway for continued expansion. My valuation model indicates that shares have limited upside. Read the full article on Seeking Alpha分析記事 • Apr 26
Paysign, Inc. (NASDAQ:PAYS) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable
Paysign, Inc. ( NASDAQ:PAYS ) shares have continued their recent momentum with a 30% gain in the last month alone. The...分析記事 • Mar 29
Here's Why We Think PaySign (NASDAQ:PAYS) Is Well Worth Watching
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...分析記事 • Jan 25
Revenues Tell The Story For PaySign, Inc. (NASDAQ:PAYS)
PaySign, Inc.'s ( NASDAQ:PAYS ) price-to-sales (or "P/S") ratio of 3.4x may not look like an appealing investment...CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$10m |
| Dec 31 2025 | US$3m | US$1m | US$8m |
| Sep 30 2025 | n/a | n/a | US$8m |
| Jun 30 2025 | n/a | n/a | US$7m |
| Mar 31 2025 | n/a | n/a | US$6m |
| Dec 31 2024 | US$1m | US$1m | US$4m |
| Sep 30 2024 | n/a | n/a | US$8m |
| Jun 30 2024 | n/a | n/a | US$8m |
| Mar 31 2024 | n/a | n/a | US$7m |
| Dec 31 2023 | US$1m | US$950k | US$6m |
| Sep 30 2023 | n/a | n/a | US$2m |
| Jun 30 2023 | n/a | n/a | US$1m |
| Mar 31 2023 | n/a | n/a | US$1m |
| Dec 31 2022 | US$3m | US$950k | US$1m |
| Sep 30 2022 | n/a | n/a | US$420k |
| Jun 30 2022 | n/a | n/a | -US$703k |
| Mar 31 2022 | n/a | n/a | -US$1m |
| Dec 31 2021 | US$963k | US$950k | -US$3m |
| Sep 30 2021 | n/a | n/a | -US$7m |
| Jun 30 2021 | n/a | n/a | -US$13m |
| Mar 31 2021 | n/a | n/a | -US$12m |
| Dec 31 2020 | US$1m | US$950k | -US$9m |
| Sep 30 2020 | n/a | n/a | -US$3m |
| Jun 30 2020 | n/a | n/a | US$6m |
| Mar 31 2020 | n/a | n/a | US$8m |
| Dec 31 2019 | US$1m | US$883k | US$7m |
報酬と市場: Markの 総報酬 ($USD 2.75M ) は、 US市場 ($USD 2.59M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Markの報酬は過去 1 年間で 20% 以上増加しました。
CEO
Mark Newcomer (60 yo)
20.2yrs
在職期間
US$2,754,265
報酬
Mr. Mark R. Newcomer co-founded PaySign, Inc., (formerly known as 3Pea International, Inc.) and serves as its President from January 24, 2024, serves as Director since May 8, 2026 and has been its Chief Ex...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder | 20.2yrs | US$2.75m | 16.11% $ 62.3m | |
| President of Patient Affordability | 5.9yrs | US$1.54m | 0.045% $ 172.6k | |
| Chief Innovation Officer | 1.2yrs | US$1.49m | 0% $ 0 | |
| CFO & Treasurer | 5.3yrs | US$697.56k | 0.69% $ 2.7m | |
| Chief Operating Officer | 2.3yrs | データなし | データなし | |
| Chief Technology Officer | 4.8yrs | データなし | データなし | |
| Chief Compliance Officer | 8.3yrs | データなし | データなし | |
| General Counsel | 7.6yrs | US$699.04k | 0.59% $ 2.3m | |
| Executive Vice President of Strategy & Corporate Development | 8.2yrs | データなし | データなし | |
| Vice President of Marketing | no data | データなし | データなし | |
| Executive VP of EFT Operations & Executive Director | 5.3yrs | データなし | 1.5% $ 5.8m | |
| Chief Payments Officer & Director | 2.3yrs | データなし | 0.34% $ 1.3m |
5.3yrs
平均在職期間
58yo
平均年齢
経験豊富な経営陣: PAYSの経営陣は経験豊富で経験豊富です（平均在職期間は5.3年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder | no data | US$2.75m | 16.11% $ 62.3m | |
| Executive VP of EFT Operations & Executive Director | 7.5yrs | データなし | 1.5% $ 5.8m | |
| Chief Payments Officer & Director | 3.8yrs | データなし | 0.34% $ 1.3m | |
| Independent Chairman of the Board | 8yrs | US$164.20k | 0.23% $ 898.8k | |
| Independent Director | 3.4yrs | US$164.20k | 0.089% $ 346.0k | |
| Non-Executive Independent Director | 8yrs | US$164.20k | 0.45% $ 1.7m | |
| Member of Advisory Board | 11.6yrs | データなし | データなし | |
| Member of Advisory Board | 11.6yrs | データなし | データなし | |
| Non-Executive Independent Director | 8.2yrs | US$164.20k | 0.46% $ 1.8m |
8.0yrs
平均在職期間
68yo
平均年齢
経験豊富なボード: PAYSの 取締役会 は 経験豊富 であると考えられます ( 8年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/27 10:42 |
| 終値 | 2026/05/27 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Paysign, Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6
| アナリスト | 機関 |
|---|---|
| Gary Prestopino | Barrington Research Associates, Inc. |
| Austin Moldow | Canaccord Genuity |
| Peter Heckmann | D.A. Davidson & Co. |